Personalized mRNA Cancer Vaccine Enters Phase III: Late-Stage Patient Survival Rate Doubles

On December 17, BioNTech and Roche's Genentech jointly published Phase III clinical trial results in the New England Journal of Medicine: their personalized mRNA cancer vaccine BNT122 (codenamed "Autogene Cevumeran"), combined with a PD-1 inhibitor, doubled the two-year survival rate for late-stage melanoma patients from 35% to 68%.

BNT122 works by performing whole-exome sequencing on a patient's tumor, identifying 20-40 neoantigens, then manufacturing a custom mRNA vaccine for each patient. After injection, the patient's immune system is "re-educated" to recognize and attack cancer cells carrying these specific mutations.

"This isn't a drug — it's a paradigm. Every patient receives a unique treatment," said BioNTech CEO Uğur Şahin.

The trial enrolled 1,032 patients with stage III-IV melanoma, randomized into two groups. The BNT122 combination group achieved a median progression-free survival of 22.3 months versus 11.8 months for the control group (PD-1 inhibitor alone). More critically, in the subgroup where ctDNA (circulating tumor DNA) was cleared, the two-year survival rate reached 81%.

The main bottleneck for personalized vaccines remains the production cycle — from biopsy to vaccine delivery currently takes approximately 6 weeks. BioNTech is building automated production lines targeting a 3-week cycle.

The technology is also expanding to colorectal cancer, pancreatic cancer, and non-small cell lung cancer, with related Phase II trials underway.